Vicore Pharma Holding AB
VCRE
NASDAQ13.78
USD
-0.13
- -
CIK
0002124403
ISIN
US92581R1041
CUSIP
92581R104
Return %
Stock
S&P500
1Y
-15.20
21.06
3Y
-15.20
70.63
5Y
-15.20
72.73
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Ahmed Mousa
- Full Time Employees
- 37
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- Kornhamnstorg 53 Solna United States of America 171 65
- IPO Date
- Jul 2, 2026
- CIK
- 0002124403
- Website
- vicorepharma.com
- Similar Companies
- Business
- Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing disease-modifying therapies for respiratory diseases, with an emphasis on the angiotensin II type 2 receptor (AT2) pathway. The company advances Buloxibutid (C21), an orally available small-molecule AT2 receptor agonist, in Phase II clinical development for idiopathic pulmonary fibrosis (IPF) and in early-phase trials for pulmonary arterial hypertension, while pursuing a portfolio of AT2-targeted programs. Vicore also develops Almee, an investigational medical device addressing the psychological impact of living with pulmonary fibrosis, currently in clinical development. The company operates through collaborations and development agreements with Emeriti Bio AB, HaLaCore Pharma AB to generate follow-on AT2-based compounds, and with Alex Therapeutics AB to develop a digital app supporting interstitial lung diseases, including IPF. Vicore originated as Mintage Scientific AB and is headquartered in Stockholm, Sweden, with research and development activities centered in Sweden and an international focus on respiratory disease therapeutics. The company’s business model centers on clinical-stage drug development, strategic partnerships, and platform expansion around AT2 receptor biology to address high-need pulmonary diseases in global markets. Vicore reports ongoing collaboration-driven progress, potential IP generation, and regulatory-oriented milestones as it advances its IP portfolio and associated medical devices in its pursuit of life-changing treatments for IPF and related conditions. Vicore’s primary geographic footprint includes Sweden, with development and operational activities pursued in Europe and potentially other regions through partnerships, licensing, and future commercialization efforts. The company maintains a focus on specialty biotechnology within the healthcare sector, pursuing growth through advancing clinical programs, strategic alliances, and expanded therapeutic modalities targeting the AT2 receptor pathway.